Leukemias
6
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
16.7%
1 terminated out of 6 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes
Refinement of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Via Cognitive Interviewing and Usability Testing
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.
Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Assess the Oral Bioavailability of New ABT-263 Formulations